BioStem Technologies, Inc. (BSEM) Misses Q2 EPS by 56c; offers outlook

BioStem Technologies, Inc. (OTC: BSEM) reported Q2 EPS of ($0.52), $0.56 worse than the analyst estimate of $0.04. Revenue for the quarter came in at $6.14 million versus the consensus estimate of $64.2 million.

2026 Financial Outlook

BioStem expects its revenue for full year 2026 to be in the range of $25 million to $29 million.

For earnings history and earnings-related data on BioStem Technologies, Inc. (BSEM) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Baird sees Tesla-SpaceX merger within 12 to 18 months
• BofA lists top 5 themes driving next $1tn in incremental semi sales